Company of the week: Relation Therapeutics
Relation sits at the top of the royalty stack, not the bottom. It holds no approved drug and almost no clinical risk, yet it is quietly assembling a royalty book on medicines that do not exist, across three different deal structures.
This post is for subscribers only
Already have an account? Sign in.